Progress in research of radiotherapy-based combined therapy for pancreatic cancer

doi:10.3877/cma.j.issn.1674-0785.2024.04.010

Abstract

Abstract:

Pancreatic cancer has high malignancy and poor prognosis. Radiotherapy is an important treatment for pancreatic cancer, and can be combined with surgery, chemotherapy, targeting, immunodrug therapy, and other treatment methods. The efficacy of monotherapy is limited. Intensive and ombined modality treatment is the trend of the future. Radiotherapy combined with other treatment methods has become a hot topic in the treatment of pancreatic cancer. This article mainly discusses the research reports of radiotherapy combined with other treatment methods for pancreatic cancer, including the methods of combination with surgery and the types of drug combination.

Key words: Pancreatic cancer, Radiotherapy, Combined therapy, Overview

Haiqiang Chu, Yuanyou Yang, Gang Ren. Progress in research of radiotherapy-based combined therapy for pancreatic cancer[J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(04): 392-396.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2024.04.010

https://zhlcyszz.cma-cmc.com.cn/EN/Y2024/V18/I04/392

References 35

1	Hue JJ, Sugumar K, Bingmer K, et al. Neoadjuvant chemoradiation may be associated with improved pathologic response in pancreatic cancer [J]. Am J Surg, 2021,221(3): 500-504.
2	Mangieri CW, Strode MA, Moaven O, et al. Utilization of chemoradiation therapy provides strongest protective effect for avoidance of postoperative pancreatic fistula following pancreaticoduodenectomy: A NSQIP analysis [J]. J Surg Oncol, 2020,122(8): 1604-1611.
3	Versteijne E, van Dam JL, Suker M, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial [J]. J Clin Oncol, 2022,40(11): 1220-1230.
4	Janssen QP, van Dam JL, Bonsing BA, et al. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial [J]. BMC Cancer, 2021,21(1): 300.
5	Eguchi H, Takeda Y, Takahashi H, et al. A Prospective, open-Label, multicenter phase 2 trial of neoadjuvant therapy using full-dose gemcitabine and S-1 concurrent with radiation for resectable pancreatic ductal adenocarcinoma [J]. Ann Surg Oncol, 2019,26(13): 4498-4505.
6	Wang D, Liu C, Zhou Y, et al. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis [J]. Radiat Oncol, 2020,15(1): 107.
7	Xu Y, Zhang Y, Wu Z, et al. Preoperative radiotherapy improves overall survival of pT4 pancreatic ductal adenocarcinoma patients after surgical resection [J]. Jpn J Clin Oncol, 2020,50(6): 679-687.
8	Sekigami Y, Michelakos T, Fernandez-Del Castillo C, et al. Intraoperative radiation mitigates the effect of microscopically positive tumor margins on survival among pancreatic adenocarcinoma patients treated with neoadjuvant FOLFIRINOX and chemoradiation [J]. Ann Surg Oncol, 2021,28(8): 4592-4601.
9	Paiella S, Malleo G, Simoni N, et al. A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma [J]. BMC Cancer, 2021,21(1): 165.
10	Kamarajah SK, Sonnenday CJ, Cho CS, et al. Association of adjuvant radiotherapy with survival after margin-negative resection of pancreatic ductal adenocarcinoma: A propensity-matched National Cancer Database (NCDB) analysis [J]. Ann Surg, 2021,273(3): 587-594.
11	You MS, Ryu JK, Huh G, et al. Comparison of efficacy between adjuvant chemotherapy and chemoradiation therapy for pancreatic cancer: AJCC stage-based approach [J]. World J Clin Oncol, 2020,11(9): 747-760.
12	Kim BH, Kim K, Jang JY, et al. Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma [J]. Eur J Surg Oncol, 2020,46(11): 2122-2130.
13	Naumann P, Ottensmeier F, Farnia B, et al. Radiographic response of vessel involvement and resectability after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer [J]. Am J Clin Oncol, 2020,43(11): 776-783.
14	Simoni N, Micera R, Paiella S, et al. Hypofractionated stereotactic body radiation therapy with simultaneous integrated boost and simultaneous integrated protection in pancreatic ductal adenocarcinoma [J]. Clin Oncol (R Coll Radiol), 2021,33(1): e31-e38.
15	Teriaca MA, Loi M, Suker M, et al. A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome [J]. Radiother Oncol, 2021,155: 232-236.
16	Tran NH, Sahai V, Griffith KA, et al. Phase 2 Trial of neoadjuvant FOLFIRINOX and intensity modulated radiation therapy concurrent with fixed-dose rate-gemcitabine in patients with borderline resectable pancreatic cancer [J]. Int J Radiat Oncol Biol Phys, 2020,106(1): 124-133.
17	Takeuchi T, Mizuno S, Murata Y, et al. Comparative study between gemcitabine-based and gemcitabine plus S1-Based preoperative chemoradiotherapy for localized pancreatic ductal adenocarcinoma, with special attention to initially locally advanced unresectable tumor [J]. Pancreas, 2019,48(2): 281-291.
18	Ioka T, Furuse J, Fukutomi A, et al. Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group trial, JCOG1106 [J]. Jpn J Clin Oncol, 2021,51(2): 235-243.
19	Ma SJ, Hermann GM, Prezzano KM, et al. Adjuvant chemotherapy followed by concurrent chemoradiation is associated with improved survival for resected stage I-II pancreatic cancer [J]. Cancer Med, 2019,8(3): 939-952.
20	吴陈陈, 曹必样, 张乐天等.放化疗联合靶向免疫治疗复发转移性胰腺癌患者的预后分析 [J]. 解放军医学院学报, 2023,44(8): 851-856.
21	蔡磊, 王先行, 王槐志胰腺癌免疫治疗的进展与瓶颈问题 [J]. 中国普外基础与临床杂志, 2023,30(9): 1030-1036.
22	Lee YH, Tai D, Yip C, et al. Combinational immunotherapy for hepatocellular carcinoma: radiotherapy, immune checkpoint blockade and beyond [J]. Front Immunol, 2020,11: 568759.
23	Khalifa J, Mazieres J, Gomez-Roca C, et al. Radiotherapy in the era of immunotherapy with a focus on non-small-cell lung cancer: time to revisit ancient dogmas? [J]. Front Oncol, 2021,11: 662236.
24	Schroter P, Hartmann L, Osen W, et al. Radiation-induced alterations in immunogenicity of a murine pancreatic ductal adenocarcinoma cell line [J]. Sci Rep, 2020,10(1): 686.
25	Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study [J]. J Clin Oncol, 2020,38(1): 1-10.
26	McCarthy PM, Rendo MJ, Uy MD, et al. Near complete pathologic response to PD-1 inhibitor and radiotherapy in a patient with locally advanced pancreatic ductal adenocarcinoma [J]. Onco Targets Ther, 2021,14: 3537-3544.
27	Du J, Lu C, Mao L, et al. PD-1 blockade plus chemoradiotherapy as preoperative therapy for patients with BRPC/LAPC: A biomolecular exploratory, phase II trial [J]. Cell Rep Med, 2023,4(3): 100972.
28	Lohse I, Kumareswaran R, Cao P, et al. Effects of combined treatment with ionizing radiation and the PARP inhibitor olaparib in BRCA mutant and wild type patient-derived pancreatic cancer xenografts [J]. PLoS One, 2016,11(12): e0167272.
29	Pereira PMR, Edwards KJ, Mandleywala K, et al. iNOS regulates the therapeutic response of pancreatic cancer cells to radiotherapy [J]. Cancer Res, 2020,80(8): 1681-1692.
30	Shimomura O, Oda T, Hashimoto S, et al. Survival impact on triple-modal strategy comprising hyperthermia, external radiation, and chemotherapy for unresectable locally advanced (UR-LA) pancreatic ductal adenocarcinoma [J]. Surg Oncol, 2021,37: 101542.
31	Rogers SJ, Datta NR, Puric E, et al. The addition of deep hyperthermia to gemcitabine-based chemoradiation may achieve enhanced survival in unresectable locally advanced adenocarcinoma of the pancreas [J]. Clin Transl Radiat Oncol, 2021,27: 109-113.
32	Mahmood J, Alexander AA, Samanta S, et al. A combination of radiotherapy, hyperthermia, and immunotherapy inhibits pancreatic tumor growth and prolongs the survival of mice [J]. Cancers (Basel), 2020,12(4): 1015.
33	Nicosia L, Alongi F, Andreani S, et al. Combinatorial effect of magnetic field and radiotherapy in PDAC organoids: A pilot study [J]. Biomedicines, 2020,8(12): 609.
34	Jo Y, Oh G, Gi Y, et al. Tumor treating fields (TTF) treatment enhances radiation-induced apoptosis in pancreatic cancer cells [J]. Int J Radiat Biol, 2020,96(12): 1528-1533.
35	Waissi W, Paix A, Nicol A, et al. Targeting DNA repair in combination with radiotherapy in pancreatic cancer: A systematic review of preclinical studies [J]. Crit Rev Oncol Hematol, 2020,153: 103060.

[1]	Dan Wang, Jian Zhu, Jun Wang, Changrui Liu, Dongliang Zhai, Yixin Liu, Yuanyuan Liu, Shanshan Ming, Qingqing He. Clinical application of intraoperative radiotherapy in breast-conserving surgery for early breast cancer [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(01): 11-17.
[2]	Xiangjun Chen, Li Yu, Xing Wang, Junqing Liang, Di Wu, Zhijun Li. Clinical efficacy study of different methods combined with radiotherapy in the repair of thin keloid [J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2024, 19(03): 215-222.
[3]	Fei Su, Liqun Jia, Feng Teng, Ying Xiong, Liwei Gao, Fuqiang Zhang, Fengjuan He, Shasha Xia, Chunyan Liu, Yanni Lou. Clinical efficacy of ulcer oil combined with compound vitamin B₁₂ solution in the prevention and treatment of radiation-induced skin injury [J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2024, 19(01): 51-56.
[4]	Lijuan Meng, Yiqun Ma, Lu Wang, Mengsi Zhang, Xin Fan, Shuilin Xu, Lihong Yang, Hui Zhu, Jinfeng Fu. Preliminary exploration of the clinical effects of radiation therapy with SRT-100 on hypertrophic scars in children [J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2024, 19(01): 16-23.
[5]	Zeying Jiang, Anting Wang, Jiaoli Wang, Ci Chen, Qiuling Zhou, Yanjuan Huang, Fang Zhou, Yan Xue, Jianfeng Zhou, Wenyong Tan, Meifang Du. Effect of multiple plant oils combination in preventing the chemoradiotherapy induced toxicities [J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2023, 18(06): 523-527.
[6]	Jianlong Liu, Zixuan Zhang, Shengjie Xu, Yunxin Zhang. Research progress on the pathogenesis and treatment of carotid blowout syndrome [J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2023, 18(05): 434-437.
[7]	DaRebai· ReDati, Lin Liu, Weimin Zhao, Tao Meng, Cheng Lei, Bo Jin, Jianjun Bi, Xinyu Li, Haijiang Wang. Clinical observation of lateral lymph node dissection after neoadjuvant chemoradiotherapy for middle and low rectal cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(04): 415-418.
[8]	Yanhui Zhang, Jiao Zhang, Zhixian Zhu. Effect of indwelling anal tube on anastomotic leakage after laparoscopic total mesangectomy after neoadjuvant chemoradiotherapy in patients with middle and low rectal cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 25-28.
[9]	Peizhong Shang, Runping Zhang, Wei Zhang, Guohong Jia, Xiaowu Li, Jianjun Miao, Bing Liu. Clinical application of novel techniques for obstructive jaundice prevention and treatment: a single-center study [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 104-107.
[10]	Jincan Huang, Di Wang, Songping Cui, Qing Chen, Shaocheng Lyu, Qiang He, Ren Lang. Predictive value of prognostic nutritional index for postoperative prognosis in patients with borderline resectable pancreatic cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(01): 51-56.
[11]	Huiying Ma, Xinling Fan, Shirui Tan, Jiayun Chen, Ying Cao, Yuan Xu, Jing Jin, Yuan Tang. Magnetic resonance linac for locally advanced rectal cancer: a preliminary experience [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 519-523.
[12]	Qiujie Shan, Lizhu Sun, Yiquan Xu, Zhixia Wang, Yan Xu, Hao Ma, Tiantian Liu. Construction and application of radiation-induced lung injury risk model for middle-aged and elderly patients with esophageal cancer during intensity modulated radiotherapy [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 388-393.
[13]	Jing Li, Guoyuan Ling, Shan Jiang, Xiaoju Chen, Xiaoyun Guo. Efficacy of pemetrexed delivery via ommaya capsule implantation versus lumbar puncture in treatment of leptomeningeal metastasis of non-small cell lung cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(02): 128-132.
[14]	Zhe Lyu, Qingkun Gao, Tianjing Chang, Hanwei Dong, Xiaopeng Wang, Manli Na, Bin Zhang. 3D-T₂WI-FFE sequence combined with curved planar reformation for assessment of effect of radiotherapy on sacral nerve morphology in patients with rectal cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(05): 513-518.
[15]	Wenbo Niu, Fengpeng Wu, Yueping Liu, Chaoxi Zhou, Juan Zhang, Xuhua Hu, Baokun Li, Gueying Wang. Neoadjuvant chemoradiotherapy for treatment of locally advanced rectal cancer: Efficacy and tumor immune microenvironment changes [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(05): 519-523.

Please choose a citation manager

Content to export